Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 8Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Warts 1

Interventions

Cyclophosphamide 35Cisplatin 24fludarabine 23Radiotherapy 23Paclitaxel 21Carboplatin 20pembrolizumab 18Nivolumab 18Magnetic Resonance Spectroscopy 18Specimen Handling 17fludarabine phosphate 15Gemcitabine 15Biopsy 15Cytarabine 14Radiation 11Filgrastim 11Doxorubicin 11Docetaxel 11Dexamethasone 11Radiosurgery 10Granulocyte Colony-Stimulating Factor 10Etoposide 10Melphalan 9Ipilimumab 9venetoclax 8Rituximab 8Calcium Dobesilate 8trametinib 7ibrutinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × 3-ingenyl angelate × Clear all
NCT00546611 2016-01-28

The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)

Peplin

Phase 1 Withdrawn

Warts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡